INTERNATIONAL DRUG DEVELOPMENT : revenue, balance sheet and financial ratios

INTERNATIONAL DRUG DEVELOPMENT is a French company founded 23 years ago, specialized in the sector Conseil pour les affaires et autres conseils de gestion. Based in PARIS (75013), this company of category PME shows in 2022 a revenue of 3.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - INTERNATIONAL DRUG DEVELOPMENT (SIREN 445038508)
Indicator 2024 2023 2022 2021 2019 2017
Revenue N/C N/C 3 010 343 € N/C N/C 1 612 814 €
Net income 368 952 € 344 875 € 207 820 € 293 524 € 696 515 € 127 963 €
EBITDA N/C N/C 519 693 € N/C N/C 48 871 €
Net margin N/C N/C 6.9% N/C N/C 7.9%

Revenue and income statement

In 2024, INTERNATIONAL DRUG DEVELOPMENT generates positive net income of 369 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 128 k€ -> 369 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

368 952 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 69%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

69.065%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

43.251%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

38.4%

Solvency indicators evolution
INTERNATIONAL DRUG DEVELOPMENT

Sector positioning

Debt ratio
69.06 2024
2022
2023
2024
Q1: 0.0
Med: 3.99
Q3: 41.75
Average

In 2024, the debt ratio of INTERNATIONAL DRUG DEVELO... (69.06) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
43.25% 2024
2022
2023
2024
Q1: 4.19%
Med: 38.81%
Q3: 76.4%
Good

In 2024, the financial autonomy of INTERNATIONAL DRUG DEVELO... (43.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
4.89 years 2022
2022
Q1: 0.0 years
Med: 0.0 years
Q3: 1.02 years
Average

In 2022, the repayment capacity of INTERNATIONAL DRUG DEVELO... (4.89) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 101.58. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

101.58

Liquidity indicators evolution
INTERNATIONAL DRUG DEVELOPMENT

Sector positioning

Liquidity ratio
101.58 2024
2022
2023
2024
Q1: 138.7
Med: 312.74
Q3: 965.51
Average

In 2024, the liquidity ratio of INTERNATIONAL DRUG DEVELO... (101.58) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
6.86x 2022
2022
Q1: 0.0x
Med: 0.0x
Q3: 0.31x
Excellent

In 2022, the interest coverage of INTERNATIONAL DRUG DEVELO... (6.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
INTERNATIONAL DRUG DEVELOPMENT

Positioning of INTERNATIONAL DRUG DEVELOPMENT in its sector

Comparison with sector Conseil pour les affaires et autres conseils de gestion

Valuation estimate

Based on 69 transactions of similar company sales in 2024, the value of INTERNATIONAL DRUG DEVELOPMENT is estimated at 2 555 179 € (range 964 780€ - 6 396 338€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
69 tx
964k€ 2555k€ 6396k€
2 555 179 € Range: 964 780€ - 6 396 338€
NAF 5 année 2024

Valuation method used

Net Income Multiple
368 952 € × 6.9x = 2 555 180 €
Range: 964 780€ - 6 396 339€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 69 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Conseil pour les affaires et autres conseils de gestion)

Compare INTERNATIONAL DRUG DEVELOPMENT with other companies in the same sector:

Voir toutes les statistiques du secteur Conseil pour les affaires et autres conseils de gestion

Frequently asked questions about INTERNATIONAL DRUG DEVELOPMENT

What is the revenue of INTERNATIONAL DRUG DEVELOPMENT ?

The revenue of INTERNATIONAL DRUG DEVELOPMENT in 2022 is 3.0 M€.

Is INTERNATIONAL DRUG DEVELOPMENT profitable?

Yes, INTERNATIONAL DRUG DEVELOPMENT generated a net profit of 369 k€ in 2024.

Where is the headquarters of INTERNATIONAL DRUG DEVELOPMENT ?

The headquarters of INTERNATIONAL DRUG DEVELOPMENT is located in PARIS (75013), in the department Paris.

Where to find the tax return of INTERNATIONAL DRUG DEVELOPMENT ?

The tax return of INTERNATIONAL DRUG DEVELOPMENT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does INTERNATIONAL DRUG DEVELOPMENT operate?

INTERNATIONAL DRUG DEVELOPMENT operates in the sector Conseil pour les affaires et autres conseils de gestion (NAF code 70.22Z). See the 'Sector positioning' section above to compare the company with its competitors.